Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
11546
Phase 2 small_molecule completed
Quick answer
Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin for Carcinoma, Hepatocellular is a Phase 2 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer HealthCare AG
- Indication
- Carcinoma, Hepatocellular
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed